Literature DB >> 1871126

Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120.

S Bhat1, S L Spitalnik, F Gonzalez-Scarano, D H Silberberg.   

Abstract

This report demonstrates that galactosyl ceramide (GalCer) or a molecule derived from it may serve as an alternative receptor for human immunodeficiency virus in the nervous system. Recombinant gp120, an envelope glycoprotein of human immunodeficiency virus type 1, specifically binds to GalCer and its derivatives. This specificity was studied by inhibiting binding of radioiodinated gp120 to GalCer with antibodies to GalCer, antibodies to gp120, and an excess of unlabeled gp120. Binding activity was also removed by absorbing gp120 with liposomes containing GalCer. In addition, studies using natural and semisynthetic lipids indicate that the linkage between galactose and ceramide is essential for binding. The significance of an alternative receptor for human immunodeficiency virus in the nervous system is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871126      PMCID: PMC52247          DOI: 10.1073/pnas.88.16.7131

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

2.  Human T-cell lymphotropic virus type III infection of the central nervous system. A preliminary in situ analysis.

Authors:  M H Stoler; T A Eskin; S Benn; R C Angerer; L M Angerer
Journal:  JAMA       Date:  1986-11-07       Impact factor: 56.272

3.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

Review 4.  The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex.

Authors:  R W Price; B Brew; J Sidtis; M Rosenblum; A C Scheck; P Cleary
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

5.  Subacute encephalomyelitis of AIDS and its relation to HTLV-III infection.

Authors:  S M de la Monte; D D Ho; R T Schooley; M S Hirsch; E P Richardson
Journal:  Neurology       Date:  1987-04       Impact factor: 9.910

6.  Multiple sclerosis-like illness occurring with human immunodeficiency virus infection.

Authors:  J R Berger; W A Sheremata; L Resnick; S Atherton; M A Fletcher; M Norenberg
Journal:  Neurology       Date:  1989-03       Impact factor: 9.910

7.  Oligodendrocyte cell adhesion molecules are related to neural cell adhesion molecule (N-CAM).

Authors:  S Bhat; D H Silberberg
Journal:  J Neurosci       Date:  1986-11       Impact factor: 6.167

8.  Productive infection of both CD4+ and CD4- human cell lines with HIV-1, HIV-2 and SIVagm.

Authors:  A Werner; G Winskowsky; K Cichutek; S G Norley; R Kurth
Journal:  AIDS       Date:  1990-06       Impact factor: 4.177

9.  Infection of brain-derived cells with the human immunodeficiency virus.

Authors:  F Chiodi; S Fuerstenberg; M Gidlund; B Asjö; E M Fenyö
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

10.  Human immunodeficiency virus in brain biopsies of patients with AIDS and progressive encephalopathy.

Authors:  F Gyorkey; J L Melnick; P Gyorkey
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

View more
  64 in total

Review 1.  Glycosphingolipid functions.

Authors:  Clifford A Lingwood
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

Review 2.  Mechanisms of resistance to HIV infection.

Authors:  W A Paxton; R A Koup
Journal:  Springer Semin Immunopathol       Date:  1997

3.  CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4.

Authors:  N Thieblemont; N Haeffner-Cavaillon; A Ledur; J L'Age-Stehr; H W Ziegler-Heitbrock; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

4.  Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.

Authors:  Y Furuta; K Eriksson; B Svennerholm; P Fredman; P Horal; S Jeansson; A Vahlne; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 5.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

6.  PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection.

Authors:  Timothy M Hanley; Wendy Blay Puryear; Suryaram Gummuluru; Gregory A Viglianti
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

7.  Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection.

Authors:  Richard D Kensinger; Bradley J Catalone; Fred C Krebs; Brian Wigdahl; Cara-Lynne Schengrund
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Mutual interactions between HIV-1 and cytokines in adherent cells during acute infection.

Authors:  A Dolei; C Serra; M V Arca; F Tilocca; M Pietravalle; L Alemanno; A Toniolo; F Ameglio
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Acyl structure regulates galactosylceramide's interfacial interactions.

Authors:  S Ali; J M Smaby; R E Brown
Journal:  Biochemistry       Date:  1993-11-02       Impact factor: 3.162

10.  The Role of Lipids in Retrovirus Replication.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  Viruses       Date:  2010-05-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.